Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to find out what the maximum tolerated dose is for an
experimental drug called AZD6918 based on the side effects experienced by patients with
advanced solid malignancies that receive daily AZD6918 alone. It is possible that AZD6918
will be administered twice daily. Then maximum tolerated doses in combination with either
gemcitabine or pemetrexed will also be investigated.